EU/3/06/381:

Human monoclonal antibody against Pseudomonas aeruginosa serotype O11 (Panobacumab)

Table of contents

Overview

On 29 June 2006, orphan designation (EU/3/06/381) was granted by the European Commission to MDS Pharma Services GB Limited, United Kingdom, for human monoclonal antibody against Pseudomonas aeruginosa serotype O11 for the treatment of pneumonia caused by serotype O11 Pseudomonas aeruginosa.

The sponsorship was transferred to Voisin Consulting, France, in July 2007 and subsequently to Envestia Limited, United Kingdom, in September 2014.

This medicine is now known as Panobacumab.

The sponsorship was transferred to Clinical Network Services (NL) B.V., the Netherlands in March 2019.

In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.

The sponsorship was transferred to Marcello Menapace in July 2021.

Key facts

Active substance
Human monoclonal antibody against Pseudomonas aeruginosa serotype O11 (Panobacumab)
Intented use
Treatment of pneumonia caused by serotype O11 Pseudomonas aeruginosa
Date of designation
29/06/2006
Orphan designation status
Positive
EU designation number
EU/3/06/381

Sponsor's contact details

Marcello Menapace
Via Due Giugno 6 
20094 Corsico (MI) 
Italy 
E-mail: mmscltd@gmail.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating